北京同仁堂股份有限公司2024年年度报告摘要

Group 1 - The company plans to distribute a cash dividend of 5.00 yuan (including tax) for every 10 shares, amounting to a total of 1,371,470,262.00 yuan, which represents 44.93% of the net profit attributable to the parent company for the year 2024 [12][13][68] - The company achieved a net profit of 1,526,274,925.98 yuan for the year 2024, with a total revenue of 1,859,728.16 yuan, reflecting a year-on-year growth of 4.12% [6][7][12] - The total assets of the company reached 3,119,752.40 million yuan, an increase of 3.68% year-on-year, while the net assets attributable to shareholders grew by 1.06% [7][12] Group 2 - The company operates in the traditional Chinese medicine sector, focusing on the production and sales of traditional Chinese medicine products, with over 400 varieties in its portfolio [3][5][6] - The company is committed to high-quality development and has implemented strategies to enhance production efficiency and investor returns [6][27][30] - The regulatory environment for traditional Chinese medicine is evolving, with new standards and guidelines being introduced to promote quality and innovation in the industry [4][5][6] Group 3 - The company has a complete industrial chain that includes planting, processing, research and development, production, logistics, and retail of traditional Chinese medicine [5][6] - The company has received approval for its profit distribution plan from the board of directors and the supervisory board, pending shareholder approval [12][54][71] - The company has engaged Zhongshun Zhonghuan Accounting Firm for auditing services, with a proposed fee of 2.56 million yuan for the 2025 fiscal year [80][89][91]